Clinical and Translational Oncology

, Volume 13, Issue 11, pp 826–830 | Cite as

Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: implications for patient outcome

  • Erdem Cubukcu
  • Omer Fatıh Olmez
  • Ozlem Saraydaroglu
  • Unsal Akcalı
  • Ozkan Kanat
  • Ender Kurt
  • Turkkan Evrensel
  • Osman Manavoglu
Research Articles



The identification of novel prognostic markers may help to better assess survival probability in different subgroups of patients with non-small-cell lung cancer (NSCLC) and to tailor treatment according to the molecular profile of the tumour.


We sought to examine whether the immunohistochemical expression of excision repair cross-complementing 1 (ERCC1), an essential component of the nucleotide excision repair pathway, may predict prognosis in NSCLC.

Material and method

Formalin-fixed paraffin-embedded tumour samples from 44 Turkish patients with NSCLC treated by adjuvant platinum-based chemotherapy were included in the study. Immunohistochemical expression levels of ERCC1 were correlated with clinical outcomes by Kaplan-Meier curves and multivariable Cox proportional hazards regression analysis.


A total of 29 patients had ERCC1-negative tumours while 15 had ERCC1-positive tumours. The mean progression-free survival (PFS) was significantly lower in patients with ERCC1-positive tumours (13±2 months) than in those with ERCC1-negative tumours (27±5 months, p<0.05). Similarly, the mean overall survival (OS) was significantly lower in patients with ERCC1-positive tumours (20±3 months) than in those with ERCC1-negative tumours (33±5 months, p<0.05). After allowance for potential confounders, Cox regression analysis demonstrated that ERCC1 expression was significantly associated with both PFS and OS (both p<0.05).


This study provides support for the prognostic value of ERCC1 immunohistochemical expression in patients with NSCLC treated by adjuvant platinum-based chemotherapy. If independently confirmed, these findings may improve prognostic stratification in this group of patients.


Non-small-cell lung cancer Excision repair cross-complementing 1 Immunohistochemistry Prognosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ettinger DS, Akerley W, Bepler G et al (2010) Non-small cell lung cancer. J Natl Compr Canc Netw 8:740–801PubMedGoogle Scholar
  2. 2.
    Janku F, Stewart DJ, Kurzrock R (2010) Targeted therapy in non-small-cell lung cancer: is it becoming a reality? Nat Rev Clin Oncol 7:401–414PubMedCrossRefGoogle Scholar
  3. 3.
    Singh N, Bal A, Aggarwal AN et al (2010) Clinical outcomes in non-small-cell lung cancer in relation to expression of predictive and prognostic biomarkers. Future Oncol 6:741–767PubMedCrossRefGoogle Scholar
  4. 4.
    Socinski MA (2010) The emerging role of biomarkers in advanced non-small-cell lung cancer. Clin Lung Cancer 11:149–159PubMedCrossRefGoogle Scholar
  5. 5.
    Gossage L, Madhusudan S (2007) Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 33:565–577PubMedCrossRefGoogle Scholar
  6. 6.
    Simon GR, Ismail-Khan R, Bepler G (2007) Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol 39:1318–1328PubMedCrossRefGoogle Scholar
  7. 7.
    Altaha R, Liang X, Yu JJ, Reed E (2004) Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 14:959–970PubMedGoogle Scholar
  8. 8.
    Vogel U, Dybdahl M, Frentz G, Nexo BA (2000) DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mRNA levels in primary lymphocytes. Mutat Res 461:197–210PubMedGoogle Scholar
  9. 9.
    Vilmar A, Sørensen JB (2009) Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer 64:131–139PubMedCrossRefGoogle Scholar
  10. 10.
    Olaussen KA, Mountzios G, Soria JC (2007) ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med 13:284–289PubMedCrossRefGoogle Scholar
  11. 11.
    Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983–991PubMedCrossRefGoogle Scholar
  12. 12.
    Kirschner K, Melton DW (2010) Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res 30:3223–3232PubMedGoogle Scholar
  13. 13.
    Ren S, Zhou S, Zhang L et al (2010) High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients. Cancer Invest 28:1078–1083PubMedCrossRefGoogle Scholar
  14. 14.
    Andressoo JO, Hoeijmakers JH, de Waard H (2006) Nucleotide excision repair and its connection with cancer and ageing. Adv Exp Med Biol 570:45–83CrossRefGoogle Scholar
  15. 15.
    Hwang IG, Ahn MJ, Park BB et al (2008) ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 113:1379–1386PubMedCrossRefGoogle Scholar
  16. 16.
    Fujii T, Toyooka S, Ichimura K et al (2008) ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer 59:377–384PubMedCrossRefGoogle Scholar
  17. 17.
    Matos LL, Trufelli DC, de Matos MG, da Silva Pinhal MA (2010) Immunohistochemistry as an important tool in biomarkers detection and clinical practice. Biomark Insights 5:9–20PubMedCrossRefGoogle Scholar

Copyright information

© Feseo 2011

Authors and Affiliations

  • Erdem Cubukcu
    • 1
  • Omer Fatıh Olmez
    • 1
  • Ozlem Saraydaroglu
    • 2
  • Unsal Akcalı
    • 3
  • Ozkan Kanat
    • 1
  • Ender Kurt
    • 1
  • Turkkan Evrensel
    • 1
  • Osman Manavoglu
    • 1
  1. 1.Department of OncologyUludag University Medical SchoolBursaTurkey
  2. 2.Department of PathologyUludag University Medical SchoolBursaTurkey
  3. 3.Department of Internal MedicineUludag University Medical SchoolBursaTurkey

Personalised recommendations